8U2E

Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide

8U2E の概要

• エントリーDOI: 10.2210/pdb8u2e/pdb
• 分子名称: Tyrosine-protein kinase BTK, (2S)-6-fluoro-5-[(3S)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]-2-(4-methylpiperazine-1-carbonyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, 1,2-ETHANEDIOL, ... (6 entities in total)
• 機能のキーワード: protein degradation, leukemia, transferase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 32337.35

構造登録者

Gajewski, S.,Clifton, M.C. (登録日: 2023-09-05, 公開日: 2024-01-31, 最終更新日: 2024-03-06)

主引用文献

Robbins, D.W.,Noviski, M.A.,Tan, Y.S.,Konst, Z.A.,Kelly, A.,Auger, P.,Brathaban, N.,Cass, R.,Chan, M.L.,Cherala, G.,Clifton, M.C.,Gajewski, S.,Ingallinera, T.G.,Karr, D.,Kato, D.,Ma, J.,McKinnell, J.,McIntosh, J.,Mihalic, J.,Murphy, B.,Panga, J.R.,Peng, G.,Powers, J.,Perez, L.,Rountree, R.,Tenn-McClellan, A.,Sands, A.T.,Weiss, D.R.,Wu, J.,Ye, J.,Guiducci, C.,Hansen, G.,Cohen, F.
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
J.Med.Chem., 67:2321-2336, 2024

PubMed Abstract: Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR signaling is a hallmark of many hematological malignancies, which makes it an attractive therapeutic target. Pharmacological inhibition of BTK enzymatic function is now a well-proven strategy for the treatment of patients with these malignancies. We report the discovery and characterization of NX-2127, a BTK degrader with concomitant immunomodulatory activity. By design, NX-2127 mediates the degradation of transcription factors IKZF1 and IKZF3 through molecular glue interactions with the cereblon E3 ubiquitin ligase complex. NX-2127 degrades common BTK resistance mutants, including BTK. NX-2127 is orally bioavailable, exhibits degradation across species, and demonstrates efficacy in preclinical oncology models. NX-2127 has advanced into first-in-human clinical trials and achieves deep and sustained degradation of BTK following daily oral dosing at 100 mg.

PubMed: 38300987
DOI: 10.1021/acs.jmedchem.3c01007

実験手法

X-RAY DIFFRACTION (1.9 Å)